Skip to main content
Advisory Service

Fractional C-Level Leadership

Part-time executive bandwidth for organizations that need senior leadership without the full-time commitment

2-3

Days per week, embedded in the leadership team

20+

Years of C-level pharma experience

3

Active mandates across biotech, MedTech, and advisory

Not every organization needs - or can justify - a full-time C-level hire. But every organization in transition needs experienced executive leadership. Fractional C-level mandates give you the strategic depth, board-level presence, and hands-on guidance of a seasoned executive at a fraction of the cost. Dr. Kurr currently serves as Fractional Chief Commercial Officer at Lemna Bio and as Fellow at THENA Capital, bringing this model to life across biotech and MedTech.

What Fractional Leadership Looks Like in Practice

Fractional C-level leadership is not consulting. It is embedded executive presence - typically 2-3 days per week - with real accountability, team ownership, and board-level authority. Dr. Kurr works as part of the leadership team, not as an external advisor looking in. This means attending board meetings, owning strategic initiatives, managing direct reports, and driving execution alongside the CEO and founding team. The model works especially well for scale-ups moving from founder-led to professionally managed, portfolio companies under investor oversight, and organizations navigating executive transitions.

Roles Dr. Kurr Fills

The most common fractional mandates are Chief Commercial Officer (CCO) - leading commercial strategy, go-to-market operations, partnerships, and revenue growth; Chief Transformation Officer (CTO) - driving end-to-end organizational transformation, operating model redesign, and digital enablement; and Chief Operating Officer (COO) - overseeing operational excellence, service delivery, and cross-functional process optimization. Dr. Kurr also serves as interim executive during leadership transitions and as a C-suite sparring partner for CEOs and founders navigating complex strategic decisions.

Why This Works for Pharma & Life Sciences

Regulated industries require executives who understand compliance, market access, medical affairs, and the unique dynamics of pharma commercialization. A fractional leader from outside the industry creates risk. Dr. Kurr brings 20+ years of direct pharma experience - at Boehringer Ingelheim, Novartis, and now across biotech and MedTech - ensuring that strategic decisions are grounded in deep domain knowledge. At Lemna Bio, he leads commercial strategy and partnership development for a computational drug design company. At THENA Capital, he provides strategic counsel to a specialist MedTech investor evaluating early-stage digital health and device companies.

The Business Case

A full-time C-level executive in pharma commands a total cost of €400-600K+ annually. A fractional mandate delivers the same caliber of leadership at 30-50% of that cost - with the flexibility to scale engagement up or down as the business evolves. For investors, this means deploying experienced operating leadership across portfolio companies without the overhead. For founders, it means accessing executive experience that would otherwise be out of reach.

What This Includes

  • Fractional Chief Commercial Officer (CCO)
  • Fractional Chief Transformation Officer (CTO)
  • Fractional Chief Operating Officer (COO)
  • Interim leadership during executive transitions
  • C-suite coaching and executive sparring
Questions

Frequently Asked Questions

Fractional C-level leadership is not consulting. It is embedded executive presence - typically 2-3 days per week - with real accountability, team ownership, and board-level authority. Dr. Kurr works as part of the leadership team, not as an external advisor looking in. This means attending board mee...

The most common fractional mandates are Chief Commercial Officer (CCO) - leading commercial strategy, go-to-market operations, partnerships, and revenue growth; Chief Transformation Officer (CTO) - driving end-to-end organizational transformation, operating model redesign, and digital enablement; an...

Regulated industries require executives who understand compliance, market access, medical affairs, and the unique dynamics of pharma commercialization. A fractional leader from outside the industry creates risk. Dr. Kurr brings 20+ years of direct pharma experience - at Boehringer Ingelheim, Novarti...

A full-time C-level executive in pharma commands a total cost of €400-600K+ annually. A fractional mandate delivers the same caliber of leadership at 30-50% of that cost - with the flexibility to scale engagement up or down as the business evolves. For investors, this means deploying experienced ope...

Let’s Connect

Interested in fractional c-level leadership or exploring how Dr. Kurr can support your organization?